6
ALL6
LB PharmaceuticalsYear
6
ALL1
20241
20221
20213
2020DEALS // DEV.
6
ALL2
Deals4
DevelopmentsCountry
6
ALL2
U.S.A4
UNITED KINGDOM6
ALL4
Not Applicable2
UndisclosedTherapeutic Area
6
ALL6
Psychiatry/PsychologyStudy Phase
6
ALL5
Phase II1
Phase IDeal Type
2
ALL1
Financing1
Series C FinancingProduct Type
6
ALL6
Small moleculeDosage Form
6
ALL2
Capsule4
OralLead Product
6
ALL2
Amisulpride3
N-Methyl Amisulpride1
N-methyl amisulprideTarget
4
ALL1
5-HT receptor2
D2/D3 receptor1
DopamineLead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $75.0 million
Deal Type : Series C Financing
LB Pharmaceuticals Closes $75M Series C as it Begins Ph II Schizophrenia Trial
Details : The net proceeds from the proposed financed will focus on the development of LB-102, which is an N-methylated analogue of amisulpride under development to treat schizophrenia.
Brand Name : LB-102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $75.0 million
Deal Type : Series C Financing
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LB Announces Publication of Phase 1 Clinical Study of LB-102
Details : LB-102, a more lipophilic version of amisulpride, was designed to improve on amisulpride’s notoriously poor membrane (BBB) permeability while matching amisulpride’s binding affinity to the D2/D3 and 5HT7 receptors (critical to the treatment of schizo...
Brand Name : LB-102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 19, 2022
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LB-102, or N-methyl amisulpride, is a patented derivative of amisulpride, a dopamine/5-HT7 antagonist successfully used to treat schizophrenia in Europe for decades.
Brand Name : LB-102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2021
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $10.0 million
Deal Type : Financing
LB Pharmaceuticals Inc Secures $10.0 Million in Additional Financing
Details : Proceeds to enable the Company’s continued clinical development of LB-102 for the treatment of schizophrenia.
Brand Name : LB-102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2020
Lead Product(s) : N-Methyl Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $10.0 million
Deal Type : Financing
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LB Pharmaceuticals Inc Announces Results of LB-102 Phase 1 First-in-Human Clinical Study
Details : LB-102 was well-tolerated up to 150 mg/day. Plasma concentrations of LB-102 were ~2.5 times greater than published values of amisulpride at the same dose, suggesting LB-102 could be dosed substantially lower than amisulpride.
Brand Name : LB-102
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2020
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The ongoing study aims to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of LB-102 in healthy volunteers.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 22, 2020
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?